Physician profile
Sunitha Urs
NPI 1245543974
$479.71
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $326 · 2020: $116 · 2021: $38.35.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $94.62 | 2019 | |
| Janssen Pharmaceuticals, INC | $90.60 | 2019-2020 | |
| Novo Nordisk INC | $60.38 | 2020-2021 | |
| Vifor Pharma, INC. | $56.02 | 2019 | |
| Advanced Respiratory, INC | $36.51 | 2019 | |
| Pfizer INC. | $34.13 | 2019-2021 | |
| Mylan Specialty L.P. | $33.47 | 2019 | |
| Sk Life Science, INC. | $24.03 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $17.71 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $17.03 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $15.21 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunitha Urs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.